Accueil / Formation Recherche / Publications / Publications Microangiopathies thrombotiques

Publications Microangiopathies thrombotiques

Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review.

Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With  Thrombotic

Increased Fatty Acid Oxidation in Differentiated Proximal Tubular Cells Surviving a Reversible Episode of Acute Kidney Injury.

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Microangiopathy Syndromes.


Urinary transcriptomics reveals patterns associated with subclinical injury of the renal allograft.

Urinary mRNA analysis of biomarkers to epithelial mesenchymal transition of renal allograft.


French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON). Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.

Thrombotic thrombocytopenic purpura. Joly BS et al. Blood 2017 May 25; 129(21): 2836-2846.

Thrombotic thrombocytopenic purpura. Kremer Hovinga JA et al. Nat Rev Dis Primers. 2017 Apr 6;3:17020.

The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope. Gilardin L et al. Haematologica. 2017 Jul 27. pii: haematol.2015.136671.

Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Grall M et al. Am J Hematol. 2017 Apr;92(4):381-387.

Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. Jamme M et al. PLoS One. 2017 May 18;12(5):e0177894.

Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Joly BS et al. Intensive Care Medicine 2017
 
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Scully M et al. J Thromb Haemost 2016
 
Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. Le Besnerais M et al. J Thromb Haemost 2016
 
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathies. Joly BS et al. Lancet Haematology 2016
 
Efficacy of rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. Benhamou Y et al. Am J Hematol 2016

Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.
 
Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
 
Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.
 
Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.
 
Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study.
 
Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.
 
Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center.
 
Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count.
 
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
 
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center.

 

ACTUALITÉS

Le Pr Eric Oksenhendler récompensé "Médecin de l'année 2018" pour son travail sur la maladie de Castleman

Calendrier 2019 de la filière MaRIH disponible !
Téléchargez le nouveau calendrier avec les dates de la filière, des centres de référence, des associations de patients et des sociétés savantes
Nouveau cas clinique "Amylose AL"
Testez vos connaissances
Voir toutes les actualités

AGENDA

Du 24-01-2019 au 25-01-2019 : Congrès de la Société d'Hématologie et d'Immunologie Pédiatrique, Chamonix


25-01-2019 : 5ème Journée Maladies Rares Hématologie - Médecine Interne, Paris


01-02-2019 : Journée annuelle du centre de référence de l'amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales, Paris
Voir tout l'agenda